Re: Ugradar et al.: Rate of re-treatment in patients treated with teprotumumab: a multicenter study of 119 patients with 1 year of follow-up (Ophthalmology. 2025;132:92-97)
Ophthalmology. 2025 Jan 16:S0161-6420(24)00758-9.
doi: 10.1016/j.ophtha.2024.12.007.
Online ahead of print.
1 Department of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, China. Electronic address: 2021220107@stu.cqmu.edu.cn.
2 Department of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, China.
3 Department of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, China. Electronic address: liuth@cqmu.edu.cn.